European Medicines Agency Counts The Cost Of Brexit
Activities To Be Restarted With Fewer Staff
As the EMA settles into its permanent headquarters in Amsterdam, it hopes that new recruits will swell its depleted staff numbers. But much will depend on the necessary expertise being available, particularly following the loss of access to experts working at the UK regulator, the MHRA.
You may also be interested in...
European Medicines Agency Restructures To Tackle New Challenges
A restructuring involving the setting up of four new task forces is aimed at improving how the European Medicines Agency responds to issues such as permanent staff reductions and challenges in regulatory science, digital business transformation, and clinical trial strategy.
Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives
Eurordis has welcomed some parts of the leaked proposals for overhauling the EU medicines legislation, but it has a number of concerns, including the future role of patient representatives if the European Medicines Agency’s committee structure is slimmed down as planned.
£10m Cash Boost For UK Regulator To Speed Up New Drug Approvals
An injection of new money should provide something of a shot in the arm for the UK’s drugs regulator as it deals with post-Brexit realities.